Khindri Sanjeev, the Chief Development Officer at Liquidia Corp, recently sold 1,101 shares of the company’s common stock. This sale, executed on October 12, 2026, was made to cover tax obligations associated with the settlement of restricted stock units (RSUs) granted to him earlier.
This transaction is significant as it highlights ongoing adjustments in executive compensation practices, particularly within the pharmaceutical industry. As companies like Liquidia navigate the complexities of stock compensation, such moves may influence how executives manage their equity stakes.
Background
Liquidia Corp, identified by the Central Index Key (CIK) 0001819576, operates within the pharmaceutical preparations sector. The company is incorporated in Delaware and has its fiscal year ending on December 31. Its business address is located at 419 Davis Drive, Suite 100, Morrisville, NC.
What the Filing Says
According to the recent filing, Sanjeev’s transaction was executed under a Rule 10b5-1 plan adopted on March 9, 2026. The filing states, "These shares of common stock were sold to cover taxes associated with the settlement of restricted stock units (RSUs) that were initially granted to the Reporting Person on February 10, 2025." Following this transaction, Sanjeev retains ownership of 64,846 shares, which includes unvested RSUs.
Impact
This sale may affect Liquidia Corp's executive compensation strategies and could set a precedent for other executives in the pharmaceutical sector. As companies adapt to changing regulations and market conditions, the management of equity stakes becomes increasingly crucial.
What's Next
The filing does not say what happens next.